What happened a year after people stopped semaglutide?
A follow-up of 327 adults examines weight change after treatment and structured lifestyle support ended.
Weight-loss research, explained
Explore the questions behind human weight-loss studies, what researchers found and what the results can—and cannot—tell us.
Semaglutide
Does semaglutide keep working after the first year?
A two-year randomized trial compares semaglutide with placebo in 304 adults without diabetes.
Semaglutide versus liraglutide: the STEP 8 comparison
A direct comparison of the two regimens over 68 weeks.
A daily semaglutide tablet: what OASIS 4 found
A trial compared daily oral semaglutide with placebo over 64 weeks.
The original STEP 1 result: how much weight did people lose?
The 68-week STEP 1 trial compared semaglutide with placebo alongside lifestyle support.
Four years of semaglutide: what SELECT tells us about maintenance
A cardiovascular trial followed weight outcomes for up to four years in adults without diabetes.
Semaglutide and weight loss with type 2 diabetes: STEP 2
STEP 2 studied weight loss with semaglutide in adults with type 2 diabetes.
Does semaglutide change hunger and cravings?
Two small randomized studies examined appetite and food intake with semaglutide.
Semaglutide and knee pain: the STEP 9 findings
Average pain score reduction at week 68; 407 adults.
Semaglutide and prediabetes: what STEP 10 measured
Average weight change at week 52; 207 adults with obesity and prediabetes.
Does semaglutide weight loss depend on feeling sick?
Participants reporting nausea; pooled STEP 1–3 analysis over 68 weeks.
Semaglutide and heart health: what SELECT found
Participants with cardiovascular death, nonfatal heart attack or nonfatal stroke; 17,604 adults.
Continuing semaglutide: what STEP 4 tells us about maintenance
Average weight change during 48 weeks after randomization; 803 participants.
Semaglutide with intensive lifestyle support: STEP 3
Average weight change at week 68; 611 adults without diabetes.
Semaglutide and daily life with obesity-related heart failure
Average questionnaire score improvement at week 52; two separate trials.
Oral semaglutide: what the earlier OASIS 1 trial found
Average weight change at week 68; 667 adults without type 2 diabetes.
Do semaglutide findings extend to Asian populations?
Four separate semaglutide studies included different Asian populations and trial settings.
Do out-of-pocket costs affect semaglutide refills?
A historical insurance-record study examined out-of-pocket costs and semaglutide refills.
Semaglutide 7.2 mg versus 2.4 mg: what STEP UP found
STEP UP compared two semaglutide trial doses and placebo in adults without diabetes.
Muscle size and function: a small STEP UP study
A small STEP UP analysis examined muscle imaging and function.
Tirzepatide
Can tirzepatide add to weight loss already achieved with lifestyle changes?
A trial studied treatment after participants first lost weight in an intensive lifestyle program.
Tirzepatide versus semaglutide: what a direct comparison found
A direct 72-week comparison of weekly tirzepatide and semaglutide in adults without type 2 diabetes.
What happened when people stopped tirzepatide?
A randomized withdrawal trial studied continued tirzepatide after initial weight loss.
When weight drops, how much is fat and how much is lean mass?
A body-composition substudy looked at fat and lean mass after weight loss.
SURMOUNT-1: the trial behind tirzepatide's weight-loss headline
A 72-week trial compared three tirzepatide doses with placebo in adults without diabetes.
Tirzepatide and weight loss with type 2 diabetes: SURMOUNT-2
A 72-week trial compared tirzepatide with placebo in adults with type 2 diabetes.
Tirzepatide and sleep apnea: what changed beyond weight?
Average reduction in apnea–hypopnea index at week 52; 469 adults across two trials.
Tirzepatide, prediabetes and three years of follow-up
Type 2 diabetes diagnoses at week 176; 1,032 participants with prediabetes.
Tirzepatide versus semaglutide outside a clinical trial
Estimated on-treatment weight change at 12 months; 18,386 matched adults.
Tirzepatide and heart failure: the SUMMIT findings
Participants with cardiovascular death or worsening heart failure; 731 adults.
Beyond the scale: what tirzepatide trial participants noticed
Interviews explored everyday experiences after participation in SURMOUNT-4.
How many people kept filling tirzepatide prescriptions?
An insurance-record study examined tirzepatide prescription coverage over six months.
Tirzepatide versus semaglutide in diabetes: what SURPASS-2 tested
SURPASS-2 compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes.
A slower start on tirzepatide did not always mean a poor result
A post hoc analysis followed selected participants whose initial weight loss was slower.
What did a weight plateau mean in tirzepatide studies?
A secondary analysis examined plateau timing among selected tirzepatide responders.
Do you need nausea for tirzepatide to work?
A post hoc analysis examined digestive symptoms and weight outcomes in four trials.
Tirzepatide and appetite: what a six-week study found
A six-week trial examined food intake and appetite with tirzepatide.
Retatrutide
Retatrutide in TRIUMPH-1: what does the 25% headline mean?
Explore the 80-week results for an investigational medicine and what a placebo comparison can show.
Retatrutide with type 2 diabetes: what TRIUMPH-2 found
TRIUMPH-2 studied investigational retatrutide in adults with type 2 diabetes.
Retatrutide’s early weight-loss trial: what did it show?
An early trial explored investigational retatrutide doses and weight loss over 48 weeks.
Other treatments
CagriSema: what REDEFINE 1 found
Average weight change at week 68; two of four groups shown, 3,417 participants overall.
Orforglipron: the daily-pill findings from ATTAIN-1
Average weight change at week 72; 3,127 adults without diabetes.
Can a pill help maintain weight loss after injections?
Estimated previous weight loss retained at week 52 among plateau participants; two prior-treatment cohorts.
Preserving lean mass during weight loss: what EMBRAZE found
Estimated difference in lean-mass loss at week 24; 102 adults randomized.
What did daily liraglutide achieve in the SCALE trial?
SCALE studied daily liraglutide alongside lifestyle support in adults without type 2 diabetes.
Liraglutide and weight loss with type 2 diabetes: SCALE Diabetes
SCALE Diabetes tested liraglutide alongside lifestyle support in adults with type 2 diabetes.
Can exercise help weight maintenance alongside liraglutide?
S-LiTE studied exercise and liraglutide after an initial low-calorie diet.
What did mazdutide achieve in the GLORY-1 trial?
GLORY-1 studied weekly mazdutide in adults with overweight or obesity in China.
After stopping a GLP medicine, what care came next?
A health-system study followed care after injectable GLP medicine prescriptions stopped.
CagriSema and type 2 diabetes: what REDEFINE 2 found
REDEFINE 2 compared CagriSema with placebo in adults with type 2 diabetes.
The early trial behind oral orforglipron
A phase 2 trial examined oral orforglipron in adults without diabetes.
Cagrilintide: an early weight-loss trial beyond GLP-1
A phase 2 trial studied cagrilintide, an amylin analogue, in adults without diabetes.
Beyond weight: what BELIEVE found about body composition
BELIEVE studied body composition and weight outcomes with experimental bimagrumab and semaglutide.
Mazdutide and diabetes: what two Chinese trials found
Two trials studied mazdutide in adults with type 2 diabetes.
Mazdutide 9 mg: an early weight-loss trial
A small phase 2 trial examined weekly mazdutide 9 mg in China.
Survodutide: what SYNCHRONIZE-1 found
A phase 3 trial compared survodutide with placebo in adults without diabetes.
Mazdutide 9 mg: the longer GLORY-2 trial
GLORY-2 studied mazdutide 9 mg in adults with obesity in China.
Mazdutide in a US trial: weight loss and tolerability
A US dose-finding trial studied mazdutide in adults without type 2 diabetes.
Beyond the scale: what patients reported about daily life
Two analyses studied patient-reported outcomes in different trial settings.